

PRODUCT SPECIFICATION

Product Name	PrEST Antigen FBXL12
Product Number	APrEST90542
Gene Description	F-box and leucine-rich repeat protein 12
Alternative Names	Fbl12, FLJ20188
Corresponding Antibodies	HPA002843
Description	Recombinant protein fragment of Human FBXL12
Amino Acid Sequence	VLGGTYRVTETGLDAGLQELSYLQRLEVLGCTLSADSTLLAISRHRLDVR KIRLTVRGLSAPGLAVLEGMPALESCLCLOGPLVTPEMPSPTEILSSCLTM PKLRVLELQGLGWEGQEA EKILCKGLPHCMVIVRAC
Fusion Tag	N-terminal His ₆ ABP (ABP = Albumin Binding Protein derived from Streptococcal Protein G)
Expression Host	<i>E. coli</i>
Purification	IMAC purification
Predicted Mw	32 kDa including tags
Usage	Suitable as control in WB and preadsorption assays using indicated corresponding antibodies.
Purity	>80% by SDS-PAGE and Coomassie blue staining
Buffer	PBS and 1M Urea, pH 7.4.
Unit Size	100 µl
Concentration	Lot dependent
Storage	Upon delivery store at -20°C. Avoid repeated freeze/thaw cycles.
Notes	Gently mix before use. Optimal concentrations and conditions for each application should be determined by the user.

 *Product of Sweden. For research use only. Not intended for pharmaceutical development, diagnostic, therapeutic or any in vivo use. No products from Atlas Antibodies may be resold, modified for resale or used to manufacture commercial products without prior written approval from Atlas Antibodies AB.*

Warranty: The products supplied by Atlas Antibodies are warranted to meet stated product specifications and to conform to label descriptions when used and stored properly. Unless otherwise stated, this warranty is limited to one year from date of sales for products used, handled and stored according to Atlas Antibodies AB's instructions. Atlas Antibodies AB's sole liability is limited to replacement of the product or refund of the purchase price. All products are supplied for research use only. They are not intended for medicinal, diagnostic or therapeutic use. No products from Atlas Antibodies may be resold, modified for resale or used to manufacture commercial products without prior written approval from Atlas Antibodies AB Rev. December 2012.